Natera agreed to acquire Foresight Diagnostics for $275 million up front with up to $175 million in contingent payments tied to revenue and reimbursement milestones. The deal brings Foresight’s PhasED-Seq phased-variant technology into Natera’s Signatera MRD platform and is intended to increase sensitivity for minimal residual disease detection, particularly in lymphoma. Natera said the combined product suite will be available for research use immediately, with clinical deployment planned in 2026, and noted ongoing use of Foresight’s Clarity MRD assay in prospective lymphoma trials. Analysts flagged the transaction as strategically accretive, bolstering Natera’s tumor-informed MRD capabilities and commercial footprint. The acquisition structure and near-term integration plans were described in company statements and investor notes cited in reporting.